Abstract
Acromegaly is a chronic systemic disorder caused by a GH-secreting pituitary adenoma. Active acromegaly results in a poor quality of life due to symptoms such as headache, fatigue, arthralgia, depression, sexual dysfunction and hyperhidrosis; an increased prevalence of co-morbidities like diabetes, hypertension as well as cancer risk and a reduced life expectancy. Appropriate, modern, multimodal treatment of acromegaly has led to a significant improvement in quality of life, an adequate control of co-morbidities and a drastic reduction in the mortality rates that used to prevail in the past. This multimodal strategy includes an adequate selection of patients who are likely to benefit from surgical treatment (which has to be performed by a skilled pituitary neurosurgeon), the use of pharmacological interventions such as somatostatin analogs and dopamine agonists, which target the pituitary adenoma; and pegvisomant, a GH mutant acting as a competitive antagonist of the GH receptor. Radiation therapy is an important tool, particularly in parts of the World where resources are limited. The ultimate outcome of the individual patient depends on the judicious use of all these treatment options, which are critically analyzed in this mini-review.
Keywords: Acromegaly, cabergoline, dopamine agonists, GH, IGF-1, lanreotide, octreotide, pegvisomant, radiation therapy, somatostatin analogs.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Volume: 14 Issue: 3
Author(s): Etual Espinosa, Claudia Ramirez and Moises Mercado
Affiliation:
Keywords: Acromegaly, cabergoline, dopamine agonists, GH, IGF-1, lanreotide, octreotide, pegvisomant, radiation therapy, somatostatin analogs.
Abstract: Acromegaly is a chronic systemic disorder caused by a GH-secreting pituitary adenoma. Active acromegaly results in a poor quality of life due to symptoms such as headache, fatigue, arthralgia, depression, sexual dysfunction and hyperhidrosis; an increased prevalence of co-morbidities like diabetes, hypertension as well as cancer risk and a reduced life expectancy. Appropriate, modern, multimodal treatment of acromegaly has led to a significant improvement in quality of life, an adequate control of co-morbidities and a drastic reduction in the mortality rates that used to prevail in the past. This multimodal strategy includes an adequate selection of patients who are likely to benefit from surgical treatment (which has to be performed by a skilled pituitary neurosurgeon), the use of pharmacological interventions such as somatostatin analogs and dopamine agonists, which target the pituitary adenoma; and pegvisomant, a GH mutant acting as a competitive antagonist of the GH receptor. Radiation therapy is an important tool, particularly in parts of the World where resources are limited. The ultimate outcome of the individual patient depends on the judicious use of all these treatment options, which are critically analyzed in this mini-review.
Export Options
About this article
Cite this article as:
Espinosa Etual, Ramirez Claudia and Mercado Moises, The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives, Endocrine, Metabolic & Immune Disorders - Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871530314666140609110308
DOI https://dx.doi.org/10.2174/1871530314666140609110308 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells: A Potent Cell Source for COVID-19
Coronaviruses Heme Oxygenase-1 against Vascular Insufficiency: Roles of Atherosclerotic Disorders
Current Pharmaceutical Design Patents on Nanoparticulate Drug Delivery Systems - A Review
Recent Patents on Drug Delivery & Formulation Various Presentations of Preeclampsia at Tertiary Care Hospital of Sindh: A Cross-Sectional Study
Current Hypertension Reviews Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Monoclonal Antibodies in Solid Tumours
Current Clinical Pharmacology Activation of the Renin-angiotensin System could Cause Hypertension During Fasting in Muslims in the Month of Ramadhan
Current Hypertension Reviews Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia
Letters in Drug Design & Discovery Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications
Current Pharmaceutical Biotechnology Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Editorial [Inflammation and Atherosclerosis: Recent Insights and Future Perspectives]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology Role of NADPH Oxidase in Hypertension and Diabetic Nephropathy
Current Hypertension Reviews